Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Political Reporter Online.
Press releases published on April 14, 2025

CGTN:中国の銀幕の転向:米国の関税政策に責がある理由
CGTNは、中国とスペインの新たな映画パートナーシップと米国映画輸入の削減がいかに対照的であるかという記事を掲載し、米国の関税戦争が、ハリウッドにとって最も有益な海外市場を危うくし、米国のより広範なサービス貿易の優位性を損なうことになる、自滅的な影響を及ぼしていることを明らかにした。 北京発, April 14, 2025 (GLOBE NEWSWIRE) -- スペインのペドロ・サンチェス (Pedro Sanchez) …

영화 산업에서 전략적 변화에 나선 중국: 미국의 관세 정책이 그 배경...CGTN
CGTN은 중국이 스페인과 체결한 영화산업 협력관계 강화가 미국 영화 수입 감축과 어떻게 대조를 이루는지에 대한 기사를 게재하였다. 이를 통해 미국의 관세 전쟁이 할리우드 영화산업이 가장 수익성이 높은 해외 시장에서의 입지를 오히려 위태롭게 하고 미국의 광범위한 서비스 무역 지배력을 약화시키는 지 자충수가 되고 있다는 그 영향을 소개하였다. 베이징, April 14, 2025 (GLOBE NEWSWIRE) -- 페드로 산체스 스페인 총리가 금요일 중국을 …

CGTN: Peralihan skrin perak China: Sebab dasar tarif AS harus dipersalahkan
CGTN menerbitkan sebuah artikel mengenai cara kerjasama baharu filem China dengan Sepanyol berbeza dengan pengurangan import filem dari AS. Artikel itu mendedahkan kesan negatif akibat perang dasar tarif Amerika yang menjejaskan pasaran asing paling …

CGTN: China's draai op het witte doek: waarom het Amerikaanse tariefbeleid hier verantwoordelijk voor is
CGTN publiceerde een artikel over hoe China's nieuwe filmpartnerschap met Spanje in contrast staat met de beperking van de import van films uit de VS. Hierin worden de contraproductieve gevolgen blootgelegd van Amerika's tarievenoorlog: Hollywoods meest …

CGTN: A Virada no Cinema Chinês: Causada pela política tarifária dos EUA
A CGTN publicou um artigo sobre como a nova parceria cinematográfica da China com a Espanha contrasta com seus cortes nas importações de filmes dos EUA, expondo o impacto autodestrutivo da guerra tarifária dos Estados Unidos – colocando em risco o mercado …

CGTN: จุดเปลี่ยนด้านจอเงินของจีน: เหตุใดจึงโทษที่นโยบายภาษีศุลกากรของสหรัฐฯ
CGTN เผยแพร่บทความเกี่ยวกับความร่วมมือใหม่ด้านภาพยนตร์ระหว่างจีนกับสเปน ซึ่งตรงข้ามกับท่าทีของจีนที่ลดการนำเข้าภาพยนตร์จากสหรัฐฯ โดยแสดงให้เห็นถึงผลกระทบแบบทำลายตนเองจากสงครามภาษีศุลกากรของสหรัฐฯ …

CGTN: Çin'in beyaz perde hamlesi: ABD'nin tarife politikası neden suçlanmalı?
CGTN, Çin'in İspanya'yla sinema alanında kurduğu yeni ortaklığın ABD'den yapılan film ithalatına getirdiği kesintilerle nasıl tezat oluşturduğunu konu edinen bir makale yayımladı ve Amerika'nın gümrük tarifesi savaşının kendi kendini baltalayan etkisini, …

Q1-2025 Production Results, Operational Highlights and Board Change
Q1-2025 Production Results, Operational Highlights and Board Change Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, is pleased to announce the Company’s first quarter …

Endeavour to Announce Its Q1 2025 Results on 1 May 2025
ENDEAVOUR TO ANNOUNCE ITS Q1 2025 RESULTS ON 1 MAY 2025 London, 14 April 2025 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) expects to release its Q1 2025 financial results on Thursday 1 May 2025, before the LSE market open. Management …

Vallourec in Exclusive Negotiations to Sell Serimax, Its Subsidiary Specializing in Welding Solutions, for €79 Million
VALLOUREC IN EXCLUSIVE NEGOTIATIONS TO SELL SERIMAX, ITS SUBSIDIARY SPECIALIZING IN WELDING SOLUTIONS, FOR €79 MILLION Meudon (France), April 14th, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces today that it has entered …

VALLOUREC ENTRE EN NEGOCIATIONS EXCLUSIVES POUR LA VENTE DE SERIMAX, SA FILIALE SPÉCIALISÉE DANS LES SOLUTIONS DE SOUDAGE, POUR 79 MILLIONS D’EUROS
VALLOUREC ENTRE EN NEGOCIATIONS EXCLUSIVES POUR LA VENTE DE SERIMAX, SA FILIALE SPÉCIALISÉE DANS LES SOLUTIONS DE SOUDAGE, POUR 79 MILLIONS D’EUROS Meudon (France), le 14 avril 2025 – Vallourec, leader mondial des solutions tubulaires premium sans soudure, …

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseases Despite FDA approval nearly a decade …